Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Total Current Liabilities: 2010-2025

Historic Total Current Liabilities for Anika Therapeutics (ANIK) over the last 15 years, with Sep 2025 value amounting to $19.1 million.

  • Anika Therapeutics' Total Current Liabilities fell 25.12% to $19.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.1 million, marking a year-over-year decrease of 25.12%. This contributed to the annual value of $23.3 million for FY2024, which is 24.96% down from last year.
  • Per Anika Therapeutics' latest filing, its Total Current Liabilities stood at $19.1 million for Q3 2025, which was up 18.71% from $16.1 million recorded in Q2 2025.
  • Over the past 5 years, Anika Therapeutics' Total Current Liabilities peaked at $47.0 million during Q1 2021, and registered a low of $16.1 million during Q2 2025.
  • Over the past 3 years, Anika Therapeutics' median Total Current Liabilities value was $25.5 million (recorded in 2024), while the average stood at $24.3 million.
  • In the last 5 years, Anika Therapeutics' Total Current Liabilities skyrocketed by 79.37% in 2021 and then slumped by 42.54% in 2022.
  • Over the past 5 years, Anika Therapeutics' Total Current Liabilities (Quarterly) stood at $29.8 million in 2021, then fell by 6.31% to $27.9 million in 2022, then grew by 11.27% to $31.1 million in 2023, then dropped by 24.96% to $23.3 million in 2024, then declined by 25.12% to $19.1 million in 2025.
  • Its Total Current Liabilities was $19.1 million in Q3 2025, compared to $16.1 million in Q2 2025 and $17.9 million in Q1 2025.